- Home
- LLY
as 07-11-2025 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 652.7B | IPO Year: | N/A |
| Target Price: | $1015.65 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 12.29 | EPS Growth: | 80.99 |
| 52 Week Low/High: | $677.09 - $972.53 | Next Earning Date: | 08-07-2025 |
| Revenue: | $49,003,200,000 | Revenue Growth: | 36.38% |
| Revenue Growth (this year): | 33.71% | Revenue Growth (next year): | 18.95% |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
MT Newswires
15 hours ago
Guggenheim Adjusts Eli Lilly and Co.'s Price Target to $942 From $936, Keeps Buy Rating
GlobeNewswire
21 hours ago
Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma
Barrons.com
21 hours ago
Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.
GlobeNewswire
a day ago
Integer Appoints Michael Coyle to Board of Directors
Insider Monkey
a day ago
Verve Therapeutics, Inc. (VERV): A Bull Case Theory
Zacks
2 days ago
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
Zacks
2 days ago
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
MT Newswires
2 days ago
Morgan Stanley Adjusts Price Target on Eli Lilly to $1,135 From $1,133, Maintains Overweight Rating
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.